Literature DB >> 8679445

Heterogeneity in renal cell carcinoma and its impact no prognosis--a flow cytometric study.

B Ljungberg1, C Mehle, R Stenling, G Roos.   

Abstract

In the process of tumour progression genetic instability is the basis for the evolution of tumour cell clones with various genotypic and phenotypic characteristics causing heterogeneity. Renal cell carcinoma has a long prediagnostic growth period, which increases the probability of clonal evolution. We have studied 200 consecutive renal cell carcinomas, addressing the interrelationship between intratumour heterogeneity and clinicopathological factors. DNA ploidy patterns were analysed in multiple samples from each tumour using flow cytometry and compared with clinical stage, tumour invasion, metastatic rate and survival. Eighty-five of 192 evaluable tumours (44%) were homogeneous concerning DNA ploidy (62% diploid, 38% aneuploid). Among 107 heterogeneous tumours a majority (79%) contained aneuploid as well as diploid cell clones. Homogeneously diploid tumours had a lower incidence of local tumour spread compared with tumours with aneuploid cell clones (P < or = 0.001), but the frequency of distant metastasis at time of diagnosis was similar. The presence of aneuploidy in at least one sample from a tumour was a significant adverse prognostic factor (P < 0.001), whereas the degree of heterogeneity had no influence on survival. The frequent heterogeneity demonstrated indicates that multiple samples must be investigated to evaluate properly the malignant character of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8679445      PMCID: PMC2074617          DOI: 10.1038/bjc.1996.326

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions.

Authors:  U Norming; B Tribukait; H Gustafson; C R Nyman; N N Wang; H Wijkström
Journal:  J Urol       Date:  1992-01       Impact factor: 7.450

2.  Intratumoral heterogeneity in DNA ploidy of esophageal squamous cell carcinomas.

Authors:  K Sasaki; T Murakami; T Murakami; M Nakamura
Journal:  Cancer       Date:  1991-12-01       Impact factor: 6.860

3.  One or multiple samplings for flow cytometric DNA analyses in breast cancer-prognostic implications?

Authors:  M Fernö; B Baldetorp; S B Ewers; I Idvall; H Olsson; H Sigurdsson; D Killander
Journal:  Cytometry       Date:  1992

4.  Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases.

Authors:  D G Skinner; R B Colvin; C D Vermillion; R C Pfister; W F Leadbetter
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

5.  The results of radical nephrectomy for renal cell carcinoma.

Authors:  C J Robson; B M Churchill; W Anderson
Journal:  J Urol       Date:  1969-03       Impact factor: 7.450

6.  Intratumoural heterogeneity of nuclear DNA-content and proliferation in clear cell type carcinomas of the kidney.

Authors:  G Baretton; B Kuhlmann; R Krech; U Löhrs
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1991

7.  Allelotype of colorectal carcinomas.

Authors:  B Vogelstein; E R Fearon; S E Kern; S R Hamilton; A C Preisinger; Y Nakamura; R White
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

8.  DNA content in renal cell carcinoma with reference to tumor heterogeneity.

Authors:  B Ljungberg; R Stenling; G Roos
Journal:  Cancer       Date:  1985-08-01       Impact factor: 6.860

9.  Intratumor variability in prognostic indicators may be the cause of conflicting estimates of patient survival and response to therapy.

Authors:  S C Barranco; R R Perry; M E Durm; A L Werner; S G Gregorcyk; W E Bolton; P Kolm; C M Townsend
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

10.  DNA content and prognosis in renal cell carcinoma. A comparison between primary tumors and metastases.

Authors:  B Ljungberg; R Stenling; G Roos
Journal:  Cancer       Date:  1986-06-15       Impact factor: 6.860

View more
  11 in total

Review 1.  Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Authors:  James Larkin; Xin Yi Goh; Marcus Vetter; Lisa Pickering; Charles Swanton
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

2.  Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma.

Authors:  Börje Ljungberg; Jan Jacobsen; Stina Häggström-Rudolfssson; Torgny Rasmuson; Gudrun Lindh; Kjell Grankvist
Journal:  Urol Res       Date:  2003-09-13

3.  Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  Front Oncol       Date:  2012-05-18       Impact factor: 6.244

4.  The free beta-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma.

Authors:  K Hotakainen; B Ljungberg; A Paju; T Rasmuson; H Alfthan; U-H Stenman
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

5.  Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray.

Authors:  Y Hedberg; B Ljungberg; G Roos; G Landberg
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

6.  SREBP1 site 1 protease inhibitor PF-429242 suppresses renal cell carcinoma cell growth.

Authors:  Tong-Bing Wang; Mei Geng; Hua Jin; Ai-Guo Tang; Hao Sun; Liu-Zheng Zhou; Bin-Hai Chen; Gang Shen; Qiang Sun
Journal:  Cell Death Dis       Date:  2021-07-20       Impact factor: 8.469

7.  Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

Authors:  Kari Hemminki; Asta Försti; Akseli Hemminki; Börje Ljungberg; Otto Hemminki
Journal:  PLoS One       Date:  2021-06-22       Impact factor: 3.240

8.  Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

Authors:  G Procopio; E Verzoni; R Iacovelli; D Biasoni; I Testa; L Porcu; F De Braud
Journal:  Br J Cancer       Date:  2012-09-11       Impact factor: 7.640

9.  Telomere shortening and mitotic dysfunction generate cytogenetic heterogeneity in a subgroup of renal cell carcinomas.

Authors:  D Gisselsson; L Gorunova; M Höglund; N Mandahl; P Elfving
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

10.  miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma.

Authors:  Bernhard Ralla; Jonas Busch; Anne Flörcken; Jörg Westermann; Zhongwei Zhao; Ergin Kilic; Sabine Weickmann; Monika Jung; Annika Fendler; Klaus Jung
Journal:  Cancers (Basel)       Date:  2018-09-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.